Background	B-O
In	B-O
patients	B-O
with	B-O
resectable	B-O
colorectal	B-O
liver	B-O
metastases	B-O
and	B-O
adjuvant	B-O
and	B-O
Cohort	B-O
2	B-O
,	B-O
insufficient	B-O
tumor	B-O
tissue	B-O
for	B-O
mutation	B-O
testing	B-O
.	B-O
The	B-O
primary	B-O
tumor	B-O
had	B-O
been	B-O
resected	B-O
prior	B-O
to	B-O
liver	B-O
resection	B-O
in	B-O
all	B-O
but	B-O
one	B-O
patient.	B-O
Twenty-three	B-O
patients	B-O
received	B-O
upfront	B-O
chemotherapy.	B-O
An	B-O
R0	B-O
liver	B-O
resection	B-O
was	B-O
achieved	B-O
in	B-O
30	B-O
of	B-O
the	B-O
31	B-O
.	B-O
On	B-O
average,	B-O
there	B-O
was	B-O
a	B-O
40.93-fold	B-O
.	B-O
The	B-O
ctDNA	B-AC
dynamics	B-O
during	B-O
neoadjuvant	B-O
chemotherapy	B-O
for	B-O
the	B-O
individual	B-O
patients	B-O
are	B-O
shown	B-O
in	B-O
Fig	B-O
3B	B-O
.	B-O
Of	B-O
the	B-O
21	B-O
patients	B-O
with	B-O
positive	B-O
ctDNA	B-AC
at	B-O
baseline,	B-O
13	B-O
had	B-O
undetectable	B-O
ctDNA	B-AC
at	B-O
T	B-O
C2	B-O
,	B-O
T	B-O
C3	B-O
,	B-O
or	B-O
T	B-O
C4	B-O
,	B-O
and	B-O
5	B-O
had	B-O
persistently	B-O
positive	B-O
ctDNA	B-AC
at	B-O
T	B-O
C4	B-O
.	B-O
Three	B-O
cases	B-O
did	B-O
not	B-O
have	B-O
T	B-O
C4	B-O
samples	B-O
collected	B-O
and	B-O
could	B-O
not	B-O
be	B-O
assessed	B-O
for	B-O
ctDNA	B-AC
clearance.	B-O
ctDNA	B-AC
remained	B-O
undetectable	B-O
at	B-O
T	B-O
C4	B-O
in	B-O
the	B-O
2	B-O
patients	B-O
with	B-O
negative	B-O
ctDNA	B-AC
at	B-O
baseline	B-O
and	B-O
neither	B-O
had	B-O
recurred	B-O
at	B-O
last	B-O
follow-up	B-O
,	B-O
but	B-O
the	B-O
study	B-O
is	B-O
underpowered	B-O
to	B-O
detect	B-O
a	B-O
difference	B-O
due	B-O
to	B-O
the	B-O
small	B-O
sample	B-O
size.	B-O
Comparing	B-O
baseline	B-O
and	B-O
post	B-O
cycle	B-O
4	B-O
restaging	B-O
CT	B-O
scans,	B-O
RECIST-defined	B-O
objective	B-O
response	B-O
was	B-O
observed	B-O
in	B-O
7	B-O
of	B-O
13	B-O
ctDNA	B-AC
positive	B-O
rate	B-O
at	B-O
baseline	B-O
was	B-O
observed	B-O
in	B-O
3	B-O
patients,	B-O
2	B-O
of	B-O
whom	B-O
remained	B-O
recurrence-free	B-O
at	B-O
last	B-O
follow-up,	B-O
60	B-O
and	B-O
82	B-O
months	B-O
after	B-O
surgery.	B-O
All	B-O
8	B-O
patients	B-O
who	B-O
had	B-O
detectable	B-O
ctDNA	B-AC
at	B-O
completion	B-O
of	B-O
adjuvant	B-O
chemotherapy	B-O
.	B-O
Two	B-O
patients	B-O
with	B-O
an	B-O
initial	B-O
negative	B-O
ctDNA	B-AC
postoperatively	B-O
developed	B-O
a	B-O
positive	B-O
test	B-O
at	B-O
completion	B-O
of	B-O
adjuvant	B-O
chemotherapy	B-O
Sankey	B-O
plot	B-O
of	B-O
ctDNA	B-AC
dynamics	B-O
with	B-O
adjuvant	B-O
chemotherapy	B-O
treatment	B-O
and	B-O
recurrence	B-O
outcome	B-O
for	B-O
the	B-O
36	B-O
patients	B-O
who	B-O
had	B-O
both	B-O
postoperative	B-O
,	B-O
but	B-O
no	B-O
difference	B-O
was	B-O
seen	B-O
for	B-O
OS	B-AC
.	B-O
Patients	B-O
with	B-O
a	B-O
positive	B-O
ctDNA	B-AC
status	B-O
after	B-O
surgery	B-O
or	B-O
at	B-O
the	B-O
end	B-O
of	B-O
all	B-O
treatment	B-O
had	B-O
a	B-O
significantly	B-O
lower	B-O
RFS	B-AC
and	B-O
OS	B-AC
compared	B-O
to	B-O
those	B-O
with	B-O
negative	B-O
ctDNA	B-AC
at	B-O
these	B-O
time	B-O
points	B-O
.	B-O
The	B-O
Kaplan–Meier	B-O
estimates	B-O
of	B-O
RFS	B-AC
at	B-O
5	B-O
years	B-O
were	B-O
16.7%	B-O
and	B-O
69.3%	B-O
for	B-O
the	B-O
postoperative	B-O
ctDNA-positive	B-O
and	B-O
ctDNA-negative	B-O
groups	B-O
RFS	B-AC
for	B-O
baseline	B-O
ctDNA	B-AC
.	B-O
A	B-O
swimmer	B-O
plot	B-O
of	B-O
serial	B-O
ctDNA	B-AC
detectability	B-O
and	B-O
clinical	B-O
outcomes	B-O
for	B-O
cohort	B-O
1	B-O
and	B-O
2	B-O
patients	B-O
is	B-O
shown	B-O
in	B-O
Fig	B-O
6B	B-O
.	B-O
Of	B-O
the	B-O
49	B-O
patients	B-O
with	B-O
both	B-O
baseline	B-O
.	B-O
Sixteen	B-O
of	B-O
the	B-O
23	B-O
patients	B-O
with	B-O
recurrence	B-O
had	B-O
blood	B-O
samples	B-O
collected	B-O
prior	B-O
to	B-O
or	B-O
at	B-O
the	B-O
time	B-O
of	B-O
recurrence,	B-O
with	B-O
ctDNA	B-AC
being	B-O
detected	B-O
in	B-O
14	B-O
of	B-O
16	B-O
RFS	B-AC
stratified	B-O
by	B-O
baseline	B-O
ctDNA	B-AC
MAF	B-AC
quartiles;	B-O
MAF	B-AC
cut-offs:	B-O
Q1	B-O
≤	B-O
0.15,	B-O
Q2	B-O
>	B-O
0.15	B-O
and	B-O
≤	B-O
1.04,	B-O
Q3	B-O
>	B-O
1.04	B-O
and	B-O
≤	B-O
7.2,	B-O
Q4	B-O
>	B-O
7.2.	B-O
.	B-O
How	B-O
to	B-O
increase	B-O
assay	B-O
sensitivity	B-O
is	B-O
an	B-O
important	B-O
question	B-O
to	B-O
address	B-O
in	B-O
future	B-O
studies.	B-O
One	B-O
potential	B-O
strategy	B-O
would	B-O
be	B-O
to	B-O
increase	B-O
the	B-O
volume	B-O
of	B-O
plasma,	B-O
another	B-O
way	B-O
would	B-O
be	B-O
to	B-O
assess	B-O
more	B-O
mutations,	B-O
as	B-O
does	B-O
the	B-O
Signatera	B-O
assay	B-O
which	B-O
involves	B-O
whole	B-O
exome	B-O
sequencing	B-O
of	B-O
the	B-O
tumor	B-O
tissue	B-O
and	B-O
then	B-O
interrogates	B-O
up	B-O
to	B-O
16	B-O
variants	B-O
in	B-O
the	B-O
plasma.	B-O
However,	B-O
to	B-O
identify	B-O
more	B-O
mutations	B-O
requires	B-O
>100	B-O
times	B-O
more	B-O
sequencing	B-O
of	B-O
the	B-O
primary	B-O
tumor	B-O
DNA,	B-O
ordering	B-O
personalized	B-O
primer	B-O
pairs	B-O
for	B-O
every	B-O
patient,	B-O
and	B-O
more	B-O
sequencing	B-O
of	B-O
plasma	B-O
DNA,	B-O
which	B-O
substantially	B-O
increases	B-O
cost.	B-O
Moreover,	B-O
the	B-O
more	B-O
mutations	B-O
analyzed,	B-O
the	B-O
more	B-O
artefactual	B-O
mutations	B-O
are	B-O
detected,	B-O
compromising	B-O
assay	B-O
specificity.	B-O
A	B-O
more	B-O
focussed	B-O
panel	B-O
such	B-O
as	B-O
our	B-O
15-gene	B-O
panel	B-O
has	B-O
several	B-O
advantages	B-O
over	B-O
genome-wide	B-O
or	B-O
exome-wide	B-O
screening	B-O
for	B-O
ctDNA	B-AC
detection,	B-O
including	B-O
lower	B-O
cost	B-O
(approximately	B-O
$1	B-O
per	B-O
patient	B-O
for	B-O
a	B-O
panel	B-O
of	B-O
primers)	B-O
and	B-O
increased	B-O
specificity.	B-O
Even	B-O
with	B-O
advances	B-O
in	B-O
ctDNA	B-AC
assay,	B-O
false	B-O
negative	B-O
results	B-O
can	B-O
still	B-O
occur	B-O
due	B-O
to	B-O
biological	B-O
factors	B-O
such	B-O
as	B-O
low	B-O
DNA	B-O
shedding	B-O
tumours,	B-O
mucinous	B-O
histology,	B-O
and	B-O
anatomical	B-O
location	B-O
of	B-O
the	B-O
occult	B-O
micrometastatic	B-O
disease.	B-O
Ultimately,	B-O
the	B-O
optimal	B-O
approach	B-O
will	B-O
have	B-O
to	B-O
balance	B-O
cost,	B-O
throughput,	B-O
and	B-O
specificity,	B-O
and	B-O
different	B-O
approaches	B-O
may	B-O
be	B-O
most	B-O
suitable	B-O
for	B-O
patients	B-O
depending	B-O
on	B-O
the	B-O
type	B-O
of	B-O
cancer,	B-O
disease	B-O
stage,	B-O
and	B-O
the	B-O
clinical	B-O
application.	B-O
Most	B-O
importantly,	B-O
prospective	B-O
studies	B-O
where	B-O
the	B-O
ctDNA	B-AC
results	B-O
are	B-O
used	B-O
to	B-O
inform	B-O
patient	B-O
management	B-O
are	B-O
required	B-O
to	B-O
define	B-O
the	B-O
value	B-O
of	B-O
a	B-O
ctDNA-guided	B-O
approach	B-O
to	B-O
patient	B-O
management.	B-O
In	B-O
summary,	B-O
we	B-O
have	B-O
confirmed	B-O
the	B-O
prognostic	B-O
significance	B-O
of	B-O
detecting	B-O
ctDNA	B-AC
at	B-O
defined	B-O
time	B-O
points	B-O
in	B-O
patients	B-O
undergoing	B-O
resection	B-O
for	B-O
CRLM	B-AC
and,	B-O
for	B-O
the	B-O
first	B-O
time,	B-O
demonstrated	B-O
the	B-O
potential	B-O
value	B-O
of	B-O
serial	B-O
analysis	B-O
during	B-O
adjuvant	B-O
therapy	B-O
and	B-O
during	B-O
surveillance	B-O
in	B-O
such	B-O
patients.	B-O
Further	B-O
studies	B-O
of	B-O
ctDNA	B-AC
in	B-O
this	B-O
population	B-O
are	B-O
required	B-O
to	B-O
demonstrate	B-O
the	B-O
clinical	B-O
utility	B-O
of	B-O
a	B-O
ctDNA-informed	B-O
approach	B-O
to	B-O
treatment	B-O
and	B-O
surveillance	B-O
strategies,	B-O
including	B-O
the	B-O
ultimate	B-O
impact	B-O
on	B-O
recurrence-free	B-O
and	B-O
overall	B-LF
survival.	B-O
Supporting	B-O
information	B-O
S1	B-O
REMARK	B-O
Checklist.	B-O
REporting	B-O
recommendations	B-O
for	B-O
tumour	B-O
MARKer	B-O
prognostic	B-O
studies	B-O
(REMARK).	B-O
(DOCX)	B-O
